vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $13.3M, roughly 1.0× OCULAR THERAPEUTIX, INC). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -488.0%, a 474.8% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -22.4%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -5.3%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
LSF vs OCUL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $13.3M |
| Net Profit | $-1.8M | $-64.7M |
| Gross Margin | 34.1% | 88.0% |
| Operating Margin | -13.5% | -526.5% |
| Net Margin | -13.2% | -488.0% |
| Revenue YoY | 15.0% | -22.4% |
| Net Profit YoY | -341.4% | -33.6% |
| EPS (diluted) | — | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $13.3M | ||
| Q3 25 | $12.9M | $14.5M | ||
| Q2 25 | $12.0M | $13.5M | ||
| Q1 25 | $11.7M | $10.7M | ||
| Q4 24 | $11.6M | $17.1M | ||
| Q3 24 | $11.8M | $15.4M | ||
| Q2 24 | $10.0M | $16.4M | ||
| Q1 24 | $9.9M | $14.8M |
| Q4 25 | $-1.8M | $-64.7M | ||
| Q3 25 | $-975.1K | $-69.4M | ||
| Q2 25 | $-362.2K | $-67.8M | ||
| Q1 25 | $-156.2K | $-64.1M | ||
| Q4 24 | $-398.4K | $-48.4M | ||
| Q3 24 | $-166.1K | $-36.5M | ||
| Q2 24 | $-239.1K | $-43.8M | ||
| Q1 24 | $-1.0M | $-64.8M |
| Q4 25 | 34.1% | 88.0% | ||
| Q3 25 | 36.5% | 87.8% | ||
| Q2 25 | 39.9% | 85.6% | ||
| Q1 25 | 41.9% | 88.2% | ||
| Q4 24 | 38.6% | 92.8% | ||
| Q3 24 | 43.0% | 89.9% | ||
| Q2 24 | 41.8% | 90.8% | ||
| Q1 24 | 40.0% | 91.0% |
| Q4 25 | -13.5% | -526.5% | ||
| Q3 25 | -7.7% | -472.3% | ||
| Q2 25 | -3.3% | -502.6% | ||
| Q1 25 | -1.9% | -597.5% | ||
| Q4 24 | -4.1% | -296.1% | ||
| Q3 24 | -2.3% | -298.2% | ||
| Q2 24 | -3.4% | -265.1% | ||
| Q1 24 | -11.0% | -214.0% |
| Q4 25 | -13.2% | -488.0% | ||
| Q3 25 | -7.6% | -477.3% | ||
| Q2 25 | -3.0% | -503.9% | ||
| Q1 25 | -1.3% | -598.7% | ||
| Q4 24 | -3.4% | -283.3% | ||
| Q3 24 | -1.4% | -236.6% | ||
| Q2 24 | -2.4% | -266.3% | ||
| Q1 24 | -10.3% | -438.9% |
| Q4 25 | — | $-0.27 | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | — | $-0.39 | ||
| Q1 25 | — | $-0.38 | ||
| Q4 24 | — | $-0.25 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.26 | ||
| Q1 24 | — | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $737.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $654.3M |
| Total Assets | $19.2M | $808.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $737.1M | ||
| Q3 25 | $5.1M | $344.8M | ||
| Q2 25 | $3.9M | $391.1M | ||
| Q1 25 | $7.0M | $349.7M | ||
| Q4 24 | $8.3M | $392.1M | ||
| Q3 24 | $7.9M | $427.2M | ||
| Q2 24 | $7.6M | $459.7M | ||
| Q1 24 | $7.1M | $482.9M |
| Q4 25 | $11.5M | $654.3M | ||
| Q3 25 | $12.8M | $258.2M | ||
| Q2 25 | $13.4M | $305.9M | ||
| Q1 25 | $13.3M | $265.9M | ||
| Q4 24 | $13.2M | $315.3M | ||
| Q3 24 | $13.1M | $352.0M | ||
| Q2 24 | $12.6M | $377.7M | ||
| Q1 24 | $12.7M | $408.0M |
| Q4 25 | $19.2M | $808.1M | ||
| Q3 25 | $18.9M | $410.9M | ||
| Q2 25 | $20.4M | $451.3M | ||
| Q1 25 | $21.5M | $405.9M | ||
| Q4 24 | $19.3M | $457.9M | ||
| Q3 24 | $18.8M | $490.4M | ||
| Q2 24 | $18.0M | $517.1M | ||
| Q1 24 | $17.6M | $538.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-54.2M |
| Free Cash FlowOCF − Capex | — | $-57.1M |
| FCF MarginFCF / Revenue | — | -430.9% |
| Capex IntensityCapex / Revenue | — | 21.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-216.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $-54.2M | ||
| Q3 25 | $1.2M | $-50.7M | ||
| Q2 25 | $-2.8M | $-55.2M | ||
| Q1 25 | $-1.3M | $-44.7M | ||
| Q4 24 | $339.2K | $-39.4M | ||
| Q3 24 | $305.8K | $-36.6M | ||
| Q2 24 | $642.7K | $-24.8M | ||
| Q1 24 | $-422.3K | $-33.9M |
| Q4 25 | — | $-57.1M | ||
| Q3 25 | — | $-56.7M | ||
| Q2 25 | — | $-56.5M | ||
| Q1 25 | — | $-46.6M | ||
| Q4 24 | — | $-39.6M | ||
| Q3 24 | — | $-36.6M | ||
| Q2 24 | — | $-25.5M | ||
| Q1 24 | — | $-34.1M |
| Q4 25 | — | -430.9% | ||
| Q3 25 | — | -390.0% | ||
| Q2 25 | — | -419.7% | ||
| Q1 25 | — | -435.6% | ||
| Q4 24 | — | -232.0% | ||
| Q3 24 | — | -237.6% | ||
| Q2 24 | — | -155.4% | ||
| Q1 24 | — | -231.1% |
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 41.2% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 18.1% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
OCUL
Segment breakdown not available.
